Fetuses with enlarged ventricles — the fluid-filled cavities inside the brain — determined by magnetic resonance imaging (MRI) scans may be less likely to benefit from surgery in the womb to treat spina bifida, according to a National Institutes of Health-supported study.

IBA (Ion Beam Applications SA) announced that it has signed a contract with the company INVAP for the installation of a proton therapy center at the Instituto de Oncologia Angel Roffo hospital in Buenos Aires, Argentina.

Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal cancer.

A recently developed drug was significantly better at detecting recurring prostate cancer in early stages, in research published in the August 2015 issue of The Journal of Nuclear Medicine. In the study, the imaging agent — Ga-68 prostate-specific membrane antigen (Ga-68 PSMA) — used with positron emission tomography and computed tomography (PET/CT), changed management in 44 percent more cases than another widely used agent.

ProTom International announced its accelerated focus on the installation of its Radiance 330 proton therapy system to be housed in the Massachusetts General Hospital ("MGH") Department of Radiation Oncology. For the first time, advanced scanning-beam technology is being installed inside a radiation-shielded vault embedded within an existing, operational radiation oncology department — a solution that enables the facility to share clinical staff, ancillary equipment and patient support areas.

Hologic Inc. announced that U.S. mammography providers gave the company and its Genius 3-D Mammography exams top scores in a new study by KLAS Research, titled Women’s Imaging 2015: Are New Technologies Delivering Promised Benefits?

A novel radiopharmaceutical probe developed at Massachusetts General Hospital (MGH) has the potential of providing physicians with information that could save the lives of patients with ischemic stroke or pulmonary embolism. Both conditions are caused when important blood vessels are blocked by a clot that has traveled from another part of the body. In a report that will appear in the October issue of the journal Arteriosclerosis, Thrombosis and Vascular Biology and has been published online, the MGH team describes using this new probe to conduct full-body scans in an animal model. Preliminary results also were reported earlier this year at the national meeting of the American Chemical Society.

3-D tomosynthesis is the latest technology to provide clearer images during screening and diagnostic procedures; however, it has not always been widely available. Hologic was the only vendor with U.S. Food and Drug Administration (FDA) approval until April of this year, when Siemens received the much-awaited green light to sell their product in the United States. In the KLAS report Women's Imaging 2015: Are New Technologies Delivering Promised Benefits?, data shows Hologic is still dominating the 3-D tomosynthesis marketplace but is facing competition from Siemens and GE. Now approved, Siemens did not waste any time upgrading their systems, and providers are responding positively. GE is not receiving the same response from users because their 3-D system is lagging due to implementation delays.